Nagoya University · 의학
Kohei Shitara 교수의 연구실은 위암 및 식도암의 표적 치료와 면역 치료 분야에서 핵심적인 연구를 수행하고 있습니다. HER2 양성 위암에서의 trastuzumab deruxtecan의 임상적 효과와 부작용에 대한 연구를 통해 새로운 치료 전략을 모색하고 있으며, HER2 음성 소작성암에서는 nivolumab을 포함한 면역관문 억제제 기반 치료의 유효성과 생존율 향상에 기여하고 있습니다. 또한, 면역치료 내성 메커니즘과 T조직형성항원 억제세포(Treg)의 역할을 규명함으로써, 치료 반응을 예측하고 보다 효과적인 치료 전략을 개발하고자 합니다.
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
Therapy with trastuzumab deruxtecan led to significant improvements in response and overall survival, as compared with standard therapies, among patients with HER2-positive gastric cancer. Myelosuppression and interstitial lung disease were the notable toxic effects. (Funded by Daiichi Sankyo; DESTINY-Gastric01 ClinicalTrials.gov number, NCT03329690.).
ClinicalTrials.gov Identifier: NCT02494583.
Standard first-line chemotherapy results in disease progression and death within one year in most patients with human epidermal growth factor receptor 2 (HER2)-negative gastro-oesophageal adenocarcinoma<sup>1-4</sup>. Nivolumab plus chemotherapy demonstrated superior overall survival versus chemotherapy at 12-month follow-up in gastric, gastro-oesophageal junction or oesophageal adenocarcinoma in the randomized, global CheckMate 649 phase 3 trial<sup>5</sup> (programmed death ligand-1 (PD-L1) co
Cancer immunotherapy involving blockade of immune checkpoint molecules, such as CTLA-4 and PD-1, has shown remarkable clinical success across several types of malignancies. However, a fraction of patients experience disease progression after treatment; thus, exploring resistant mechanisms for immune checkpoint inhibitors and improving their treatment outcome with additional modalities are of great importance. CD4<sup>+</sup> regulatory T (T<sub>reg</sub> ) cells characterized by expression of th
Some features were associated with favorable response to nivolumab for AGC. Combining these features might be useful to predict efficacy.
